Oshaughnessy 2001

1 Treatments

**Studied treatment** intermittent oral capecitabine 1,255 mg/m² twice daily (two weeks’ treatment followed by a one-week rest period)

**Control treatment** intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil [5-FU]) administered every three weeks

**Concomittant treatments** -

2 Patients

**Patients** first-line therapy for advanced/metastatic breast cancer

**Inclusion criteria** -

**Exclusion criteria** -

3 Methods

**Blinding** -

**Design** -

**Centers** -

**Geographical area** -

**Sizes** -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References